COMMUNIQUÉ DE PRESSE
News
-
-
COMMUNIQUÉ DE PRESSE
Carl Zeiss Meditec achieves slight revenue growth in first quarter of 2023/24
Carl Zeiss Meditec AG achieved 1.0% revenue growth in the first quarter of fiscal year 2023/24, reaching €475.0m. Earnings before interest and taxes (EBIT) declined to around €43.5m, with the EBIT margin at 9.2%. Revenue growth was primarily boosted by the equipment business and SBU Microsurgery -
COMMUNIQUÉ DE PRESSE
Aperam - Résultats du troisième trimestre 2023: 'Le marché de l'acier inoxydable en crise, Alliages, Recyclage et Renouvelables donnent des résultats'
Aperam annonce une baisse des expéditions, de l'EBITDA ajusté et du bénéfice net pour l'année 2023, tout en faisant état de gains annualisés pour le quatrième trimestre 2023. Les perspectives pour le 1er trimestre 2024 restent prudentes malgré une légère amélioration du marché au quatrième trimestre 2023 -
COMMUNIQUÉ DE PRESSE
Aperam - Full year and fourth quarter 2023 results: “Stainless Market in Crisis, Alloys, Recycling & Renewables Deliver””
Aperam announces full year and fourth quarter 2023 results with a focus on challenges in the stainless market and the performance of its strategic initiatives -
COMMUNIQUÉ DE PRESSE
Wenchang, Hainan Takes Flight as the Visionary 'City of the Future' Igniting a Thriving Aerospace Industry
Wenchang, China, is experiencing a surge in space-themed tourism, with the Long March-7 Y8 launch making it popular. The city has seen increased tourism, job creation, and economic growth due to its aerospace industry -
COMMUNIQUÉ DE PRESSE
duPont REGISTRY Group Welcomes Colleen Cash as President of Sotheby's Motorsport and Chief Digital Officer of duPont REGISTRY Group
duPont REGISTRY Group and RM Sotheby's appoint Colleen Cash as President of Sotheby's Motorsport and Chief Digital Officer of duPont REGISTRY Group, creating a cohesive experience for both platforms, marking a significant milestone in duPont REGISTRY Group's commitment to elevating the luxury automotive marketplace -
-
COMMUNIQUÉ DE PRESSE
Intellipharmaceutics International Inc. Announces Stock Option Grant
Intellipharmaceutics International Inc. issued 1,910,000 common share purchase options to certain eligible individuals under the stock option plan. The options vest over a period of 2 years and expire on February 5, 2034 -
-
COMMUNIQUÉ DE PRESSE
Applied DNA Announces First Quarter Fiscal Year 2024 Financial Results
Applied DNA Sciences, Inc. (NASDAQ:APDN) announces Q1 fiscal year 2024 financial results and progress on GMP production capacity for mRNA therapeutics. Projects initial facility capacity to enable up to $15 million Linea IVT revenue annually
